Analysis of Securities Fraud Lawsuit at Outset Medical, Inc.

LOS ANGELES,
Oct. 11, 2024 /PRNewswire/ —
Glancy Prongay & Murray LLP (“GPM”) notifies investors with substantial losses of the opportunity to take the lead in the securities fraud class action lawsuit concerning Outset Medical, Inc. (“Outset Medical” or the “Company”) with the ticker symbol OM.

Class Period:
August 1, 2022 –
August 7, 2024


Lead Plaintiff Deadline:
October 28, 2024

Investors wishing to spearhead the Outset Medical lawsuit may provide their contact information at www.glancylaw.com/cases/Outset-Medical-Inc-1/.
For further details on rights, reach out to the GPM representative, Charles H. Linehan, at 310-201-9150, Toll-Free at 888-773-9224, or through email at shareholders@glancylaw.com.

The complaint asserts that during the Class Period, Defendants concealed from investors critical information regarding Outset Medical, including issues with FDA approval, risks associated with product sales, and misleading statements about the Company’s performance.

Stay updated via LinkedIn,
Twitter, or
Facebook.

To be part of the class action, no immediate action is required. You can engage your chosen counsel, remain an absent member, or seek further information about the lawsuit by contacting Charles Linehan, Esquire, of GPM.

For any inquiries regarding this lawsuit, contact Charles Linehan at 310-201-9150 or 888-773-9224, email shareholders@glancylaw.com, or visit www.glancylaw.com.
For email inquiries, provide your mailing address, telephone number, and the number of shares purchased.

This communication may constitute Attorney Advertising in specific jurisdictions pursuant to applicable laws.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com